In cross-trial post hoc analysis with mixed-effect model repeated measure adjustment, no evident differences in Week 24 endpoints (CDAI, DAS28-CRP, CRP, hemoglobin, pain VAS, FACIT-Fatigue) between patients receiving sarilumab with vs without MTX.
CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making
ACR 2020: SEAM-RA trial on switch to ETN or MTX monotherapy vs continued combination therapy in RA patients with stable remission, as reported by CCO
San Antonio cohort study from ACR 2020 on potential cardiotoxicity of hydroxychloroquine in patients with rheumatoid arthritis (RA), as reported by CCO
Pharmacogenomics biomarkers may be useful in predicting the response to methotrexate among patients with early RA in a machine learning model: ACR 2020 study reported by CCO